These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2609846)

  • 1. [Myoclonus during a course with buflomedil treatment].
    Lucas C; Soetaert G; Leys D; Petit H
    Acta Clin Belg; 1989; 44(5):360-1. PubMed ID: 2609846
    [No Abstract]   [Full Text] [Related]  

  • 2. [Myoclonus during treatment with buflomedil].
    Leys D; Pavy G; Bourgeois P; Petit H
    Therapie; 1985; 40(6):481. PubMed ID: 4089790
    [No Abstract]   [Full Text] [Related]  

  • 3. [Myoclonic coma and severe cardiac insufficiency in a patient with arteritis].
    Blain H; Jeandel C
    Rev Med Interne; 2001 Jun; 22 Suppl 2():247s-249s. PubMed ID: 11433584
    [No Abstract]   [Full Text] [Related]  

  • 4. Anaphylactic reactions to buflomedil.
    Scala E; Guerra EC; Pirrotta L; Giani M; De Pità O; Puddu P
    Allergy; 1999 Mar; 54(3):288-9. PubMed ID: 10321569
    [No Abstract]   [Full Text] [Related]  

  • 5. [Myoclonic encephalopathy in a patient treated with an excessive dose of buflomedil].
    Presse Med; 1983 May; 12(23):1492. PubMed ID: 6222351
    [No Abstract]   [Full Text] [Related]  

  • 6. [Reversible neurologic toxicity of buflomedil overdosage].
    Otmane-Telba M; Gury B; Paulien R; Feret J; Nouailhat F
    Presse Med; 1985 Feb; 14(5):286. PubMed ID: 3157120
    [No Abstract]   [Full Text] [Related]  

  • 7. Buflomedil: still seizures and cardiac disorders. Too many patients are exposed to an unjustified risk of serious adverse effects.
    Prescrire Int; 2007 Feb; 16(87):15. PubMed ID: 17323522
    [No Abstract]   [Full Text] [Related]  

  • 8. Buflomedil in arterial occlusive disease: results of a controlled multicenter study.
    Trübestein G; Balzer K; Bisler H; Klüken N; Muller-Wiefel H; Unkel B; Mahfoud Y; Ziegler W
    Angiology; 1984 Aug; 35(8):500-5. PubMed ID: 6383127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Acute severe coronary insufficiency during intravenous therapy with buflomedil hydrochloride. Description of 4 cases].
    Romanò M; Spinelli A; Muzio L; Cazzani E; Baldini MR
    Minerva Cardioangiol; 1988 Sep; 36(9):451-5. PubMed ID: 3226575
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety profile assessment of buflomedil: an overview of adverse reactions between 1975 and 2011.
    Bucolo C; Longo L; Camillieri G; Drago F; Salomone S
    Pharmacoepidemiol Drug Saf; 2012 Nov; 21(11):1190-6. PubMed ID: 22855302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buflomedil: still too many fatal cardiac and neurological events.
    Prescrire Int; 2011 Apr; 20(115):99. PubMed ID: 21648214
    [No Abstract]   [Full Text] [Related]  

  • 12. Double-blind placebo-controlled trial of buflomedil in the treatment of Raynaud's phenomenon: six-month follow-up.
    Le Quentrec P; Lefebvre ML
    Angiology; 1991 Apr; 42(4):289-95. PubMed ID: 1673051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of buflomedil on behaviour, memory, and intellectual capacity in patients with dementia. A placebo-controlled study.
    Levinson B; Wright P; Barklem S
    S Afr Med J; 1985 Aug; 68(5):302-7. PubMed ID: 3898413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of buflomedil perfusion on peripheral tissue oxygenation during transluminal angioplasty in patients with advanced arteriopathy of the lower limbs].
    Joffre F; Meites G; Rousseau H; Staffin C; Allaert FA; Pelat P
    Ann Radiol (Paris); 1994; 37(3):239-44. PubMed ID: 8092756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicentre clinical placebo-controlled study with buflomedil in the treatment of mild dementia of vascular origin.
    Cucinotta D; Aveni Casucci MA; Pedrazzi F; Ponari O; Capodaglio M; Valdina P; Toxiri I; Bartorelli L; Granata Q; Franzini C
    J Int Med Res; 1992 Apr; 20(2):136-49. PubMed ID: 1521670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Encephalotropic and psychotropic effects of intravenous buflomedil in the elderly: double-blind, placebo-controlled pharmaco-EEG and psychometric studies.
    Saletu B; Grünberger J; Linzmayer L; Stöhr H
    Int J Clin Pharmacol Res; 1984; 4(2):95-107. PubMed ID: 6469443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of population pharmacokinetics and simulation for postmarketing safety evaluation of dosing guidelines for drugs with a narrow therapeutic index: buflomedil as a case study.
    Bourguignon L; Ducher M; Matanza D; Bleyzac N; Uhart M; Odouard E; Maire P; Goutelle S
    Fundam Clin Pharmacol; 2012 Apr; 26(2):279-85. PubMed ID: 22004557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Myoclonic encephalopathy in a patient treated with an excessive dose of buflomedil].
    Treves R; Desproges-Gotteron R
    Presse Med; 1983 Mar; 12(10):645. PubMed ID: 6220294
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinical experimentation with a new vasodilator: cinepazide maleate in arterial diseases of the lower limbs].
    Warembourg G; Carre A; Ginestet A; Lambert M
    Lille Med; 1976 Dec; 21 Suppl 4():898-901. PubMed ID: 1018614
    [No Abstract]   [Full Text] [Related]  

  • 20. A review of long-term safety data with buflomedil.
    Bachand RT; Dubourg AY
    J Int Med Res; 1990; 18(3):245-52. PubMed ID: 2193838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.